共 50 条
CAR T cell therapy
被引:5
|作者:
Hosen, Naoki
[1
]
机构:
[1] Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Osaka, Japan
关键词:
CAR T cell;
Cancer;
immunotherapy;
CD19;
Integrin;
beta7;
CD19;
REMISSIONS;
D O I:
10.1080/25785826.2020.1796063
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody's antigen recognition site with costimulatory molecules such as CD28 and CD3 zeta. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells. The effect of CD19-targeted CAR T cells on B-cell hematologic cancer is surprising and has already been approved in many countries including Japan. More targets for several kinds of cancers are being searched now. We have also shown that CAR T cells specific for activated integrin beta 7 are highly effective for multiple myeloma in pre-clinical tests.
引用
收藏
页码:69 / 73
页数:5
相关论文